📊 poll results
Moderna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?
🗳️ 12 votes so far 🏆 Leading: The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base

Of 12 votes cast so far, The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base leads with 42%.

This is mostly a short squeeze and momentum rally -- with $5.5B in shorts getting burned, the stock's valuation has now outrun its actual shrinking sales is second on 33%, 9 points behind.

Everyone who has answered so far is voting from China.

The most recent vote came in 6 days ago.

hewsay who say wut? 💬
📊 poll results
Moderna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?
42%
Leading answer
The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base
12 votes so far
hewsay.com ↗

Discussion

Vote on one of these nextModerna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?Moderna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?48% of Americans hope AI cures cancer or Alzheimer's — but only 15% trust the companies building it. Is that optimism justified?
react to this tea 👀
The cancer vaccine data is a legitimate scientific breakthrough -- a personalized mRNA shot that meaningfully delays melanoma recurrence changes the long-term story for Moderna
The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base
This is mostly a short squeeze and momentum rally -- with $5.5B in shorts getting burned, the stock's valuation has now outrun its actual shrinking sales